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Much controversy surrounds the choice of optimal
candidates for the prophylaxis of respiratory syn-
cytial virus (RSV) based on published cost-effective
measurements. The measurement of indirect costs
associated with chronic illness is increasingly being
recognized as a critical portion in understanding
total health-care costs. The addition of indirect cost
information to current cost-effectiveness ratios can
potentially alter the approval coverage for treat-
ment by payer groups.
RSV is a highly prevalent condition among 
children that can affect primary caregivers’ produc-
tivity. The aggregate cost of providing prophylaxis
for infants at risk for RSV is substantial, but the eco-
nomic consequences of lost and reduced productiv-
ity for caregivers of this population can also be
sizable. RSV is the leading cause of childhood hos-
pitalizations, costing the United States over $300
million [1]. Monthly prophylaxis using palivizumab
(Synagis®) or RSV-IGIV (Respigam®) has proven
effective in reducing the risk of RSV, RSV hospitali-
zations, and associated direct medical costs.
Cost-effective analyses have left many employers
and managed care groups challenged to ﬁnd the
optimal balance of providing prophylaxis to certain
infant candidates. According to the American
Academy of Pediatrics (AAP) policy statement on
RSV, only certain infants with prematurity (gesta-
tional age) and/or other risk factors are recom-
mended for prophylactic treatment for the
prevention of RSV [2]. The policy statement states
in its recommendations that “given the large
number of patients born between 32 and 35 weeks
and the cost of the drug, the use of palivizumab in
this population should be reserved for those infants
with additional risk factors until more data are
available.” The cost beneﬁt analyses supporting this
recommendation suggest that both the cost and the
logistics associated with prophylaxis for this subset
of infants may outweigh the potential cost beneﬁts.
Many organizations have been modifying the AAP’s
recommendations to create their own guideline cri-
teria for determining prophylactic treatment for
RSV almost exclusively based on direct medical and
pharmacy costs [3]. An increasing number of orga-
nizations have begun to include indirect productiv-
ity costs in assessing the cost beneﬁt of chronic
conditions. This more inclusive method is viewed as
an investment in human capital that promotes a
healthier and more productive workforce.
Additional information assessing the indirect
costs associated with RSV hospitalizations can aid
employer groups and managed care organizations
in estimating the overall cost burden and better
identifying candidates for prophylaxis. One such
study attempting to address the issue surrounding
lost time and out-of-pocket costs associated with
RSV hospitalizations is presented in this issue of
Value in Health by Leader et al. [4]. The study
begins to address the addition of indirect costs for
RSV prophylaxis treatment evaluation. The article
sheds light on the time and out-of-pocket costs asso-
ciated with RSV hospitalizations for speciﬁc cohorts
of infants that have not received prophylaxis for
RSV. Issues not addressed in this study include the
actual lost time and costs directly related to missed
work. The survey identiﬁed the time and out-of-
pocket costs for the primary caregiver and up to
four additional family members (or friends) who
were affected by the infant’s hospitalization episode.
These total costs for all the persons involved were
used to estimate the societal burden associated with
the hospitalizations.
An employer group or managed care organiza-
tion would be most interested in assessing the pro-
ductivity costs associated with either the primary
cardholder (employee) or the primary caregiver, not
the total societal burden. To assist employer groups
or managed care organizations in utilizing the 
productivity cost information to justify the need to
treat additional infant subpopulations with RSV
prophylaxis, further studies would need to assess
the work-related productivity costs alone. Adding
the Work Limitations Questionnaire to surveys on
personal time and out-of-pocket costs would better
quantify the impact of RSV hospitalizations on
work-related productivity [5].
While the article makes an important contribu-
Volume 6 • Number 2 • 2003
V A L U E  I N  H E A L T H
Indirect Costs of Respiratory Syncytial Virus
Hospitalizations:A Commentary
Andrea S. Marks, MS
Analytics & Outcomes Research, Caremark, Inc.
© ISPOR 1098-3015/03/$15.00/98 98–99
99Indirect Costs of RSV Hospitalizations
tion to the challenging task of assessing indirect
costs, its statistical analysis is problematic. First, it
is apparent that there exists an outlier within the
premature infant cohort with an associated hospi-
talization length of stay (LOS) of 45 days. This
drives the mean LOS for that group to 7 days. If
one were to exclude the outlier, the average LOS for
that group would be closer to 6.2 days. At one point
in the discussion, the authors do recognize the
outlier, but then continue to include it in the time
and cost evaluations. Without the assumed outlier,
the means for the premature infant cohort would
decrease by approximately 10%. In groups where
there is extensive variability, it is more meaningful
to use the median rather than the mean to make
comparisons. For example, the mean out-of-pocket
costs for the premature group is $644, three times
the mean for the full-term infants. However, the
median out-of-pocket cost for the premature infants
is $216, only 1.65 times as great as the median of
$131 for the full-term infants. The authors are
careful to always present the medians along with
the means, but the comparisons and statistical tests
are made on the basis of the means. This has the
effect of exaggerating the differences between the
two groups.
A second analytic problem is the inappropri-
ate comparison of a group of premature infants
(33–35 weeks gestational age) to a group of full-
term infants. The authors do state that the two
groups are “not truly comparable since the full-term
infants were only enrolled at one participating hos-
pital” and that the sample was not powered for sta-
tistical evaluation. It may be correct that the losses
in productivity are substantially higher for the pre-
mature group than the full-term group, but this
analysis does not support that generalization.
To assist groups in making future recommenda-
tions for extending RSV prophylaxis for additional
infant subpopulations (i.e., 33–35 weeks of gesta-
tional age with no other apparent risk factors), a
comparative study on the productivity costs associ-
ated with RSV hospitalization for those receiving
prophylaxis versus those infants not receiving pro-
phylaxis would be necessary. Further studies should
be conducted validating the survey collection
methods, as well as incorporating additional pre-
RSV hospitalization costs (productivity costs, ofﬁce
visits, emergency room visits) and true productivity
losses from a payer perspective.
The current debate around the cost-effectiveness
of RSV prophylaxis is handicapped by the omission
of indirect productivity costs. Employers and some
managed care organizations could more clearly
identify candidates who would beneﬁt from RSV
prophylaxis therapy if the quantiﬁcation of work-
related costs, such as lost time, lost productivity,
and lost income, was improved. The study pre-
sented by Leader et al. demonstrates that an addi-
tional cost burden does exist in the population
hospitalized for RSV and paves the way for addi-
tional studies. I commend the authors on taking
steps toward understanding the societal burden a
severe childhood illness can have.
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